To Observe the Clinical Effect of press-needle combined withAdemetionine 1,4 - Butanedisulfonate for Injection in the Treatment of hepatocellular Jaundice

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900022386

Enrollment

Unknown

Registered

2019-04-09

Start date

2018-01-01

Completion date

Unknown

Last updated

2019-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular jaundice

Interventions

Control group:Ademetionine 1,4 - Butanedisulfonate for Injection

Experimental group:Ademetionine 1,4 - Butanedisulfonate for Injection + press-needle

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) all patients met the diagnostic criteria for hepatocellular jaundice: 0.2 < CB/STB < 0.5, 34.2umol/L < STB < 382umol/L, and the urine bilirubin was positive; (2) Aged 18-70 years old; (3) complete clinical data; The patients themselves and their families knew about this study.

Exclusion criteria

Exclusion criteria: (1) malignant tumor patients or have other serious basic disease or infection; (2) autoimmune liver disease caused by; (3) stones, tumors, congenital structural abnormalities and other factors leading to intrahepatic and extrahepatic bile duct obstruction; (4) press needle local skin infection or skin injury should not be used.

Design outcomes

Primary

Measure	Time frame
serum total bilirubin;Alanine aminotransferase;Symptom scores;	—

Countries

China

Contacts

Public ContactLongjie Lv

Yantai Infectious Disease Hospital

longjie2825@126.com+86 15589506007

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026